Levosert Shi

Levonorgestrel, the active ingredient in Levosert Shi, is a progestin presented as an intrauterine system for intrauterine use. The device releases levonorgestrel locally over several years, providing reliable contraception for women of reproductive age and reducing menstrual bleeding.

GNH USA supplies Levosert Shi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across all markets.

Levosert Shi delivers levonorgestrel to the uterine cavity and is indicated for hormonal contraceptive and menstrual management pathways. - Contraception: prevents pregnancy in women of reproductive age through sustained hormone release. - Heavy menstrual bleeding: reduces menstrual blood loss and improves anemia associated with excessive bleeding. - Endometrial protection during estrogen therapy: prevents estrogen‑induced endometrial hyperplasia in women receiving combined hormone regimens.

Levosert Shi may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Irregular vaginal bleeding or spotting - Amenorrhea (absence of periods) - Pelvic or abdominal cramping - Breast tenderness

Serious or Rare Side Effects: - Uterine perforation during insertion - Device expulsion or displacement - Severe allergic reaction (anaphylaxis)

Before using Levosert Shi, clinicians should observe several safety measures. - Pregnancy testing: confirm non‑pregnant status before device insertion. - Uterine evaluation: perform ultrasound to rule out anomalies or fibroids that may impede placement. - Infection screening: assess for active pelvic infection; treat before insertion. - Follow‑up visits: schedule post‑insertion checks to verify correct positioning. - Contraindications review: avoid use in women with known hypersensitivity to levonorgestrel or uterine malignancy. - Store at room temperature: keep the device in its original packaging, protect from moisture and direct sunlight.

Levosert Shi can interact with other medicines that affect hormone metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): may markedly reduce contraceptive efficacy. - Enzyme‑inducing antiepileptics: can accelerate levonorgestrel metabolism, increasing failure risk.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., tetracycline, metronidazole): may slightly lower hormone levels; advise backup contraception. - Antifungal azoles (e.g., ketoconazole): potential modest reduction in effectiveness. - Herbal supplements such as St. John’s wort: may diminish hormone exposure; monitor for breakthrough bleeding.